Evidence map›Paper›PMID 26136397›Full record

ArticleLiver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society2015

Risk factors and outcomes of carbapenem-resistant Klebsiella pneumoniae infections in liver transplant recipients.

Marcus R Pereira, Brendan F Scully, Stephanie M Pouch, Anne-Catrin Uhlemann, Stella Goudie, Jean E Emond, Elizabeth C Verna

Open access · bronzeAbstract read
In one paragraph

Article in Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed, 6 pooled it
6.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 6 syntheses or guidelines pooled it, 101 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Article
  9. Article
  10. Article
  11. Article
  12. Carbapenem-resistantWorld journal of gastroenterology · 2025
    Article
  13. Review
  14. World journal of hepatology · 2024
    Article
  15. New Antibiotics Against Multidrug-Resistant Gram-Negative Bacteria in Liver Transplantation: Clinical Perspectives, Toxicity, and PK/PD Properties.Transplant international : official journal of the European Society for Organ Transplantation · 2024
    Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Observational
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Marcus R PereiraDivision of Infectious Diseases.
Brendan F ScullyDepartment of Medicine.
Stephanie M PouchDepartment of Medicine, Wexner Medical Center, The Ohio State University, Columbus, OH.
Anne-Catrin UhlemannDivision of Infectious Diseases.
Stella GoudieCenter for Liver Disease and Transplantation, Columbia University Medical Center, New York, NY.
Jean E EmondDepartment of Surgery.
Elizabeth C VernaDepartment of Medicine.
Columbia University Irving Medical Center · USOffice of Infectious Diseases · USThe Ohio State University Wexner Medical Center · US

Funding

Carbapenem-resistant bacterial colonization and infection after liver transplantR01AI116939 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI UHLEMANN, ANNE-CATRIN · 2015 to 2019
$2.4M
Research: Antimicrobial Resistance (RMI)P20RR020616 · NCRR · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI LARSON, ELAINE LUCILLE · 2004 to 2006
$1.7M
NCRR NIH HHS P20 RR020616NIAID NIH HHS R01 AI116939
6 · The paper itself

Abstract

Carbapenem-resistant Klebsiella pneumoniae (CRKP) infection is increasing in incidence and is associated with increased mortality in liver transplantation (LT) recipients. We performed a retrospective cohort study of all patients transplanted between January 2010 and January 2013 to identify the incidence and risk factors for post-LT CRKP infection and evaluate the impact of this infection on outcomes in a CRKP-endemic area. We studied 304 recipients, of whom 20 (6.6%) developed CRKP and 36 (11.8%) carbapenem-susceptible Klebsiella pneumoniae (CSKP) infections in the year following LT. Among the 20 recipients with post-LT CRKP infection, 8 (40%) were infected in ≥ 2 sites; 13 (65%) had surgical site-intra-abdominal infections; 12 (60%) had pneumonia; and 3 (15%) had a urinary tract infection. There were 6 patients with a CRKP infection before LT, 5 of whom developed a CRKP infection after LT. Significant risk factors for post-LT CRKP infection in multivariate analysis included laboratory Model for End-Stage Liver Disease at LT (odds ratio [OR], 1.07; P = 0.001), hepatocellular carcinoma (OR, 3.19; P = 0.02), Roux-en-Y biliary choledochojejunostomy (OR, 3.15; P = 0.04), and bile leak (OR, 5.89; P = 0.001). One-year estimated patient survival was 55% (95% confidence interval, 31%-73%), 72% (55%-84%), and 93% (89%-96%), for patients with CRKP, CSKP, and no Klebsiella pneumoniae infection, respectively. In multivariate analysis, CRKP (hazard ratio [HR], 6.92; P < 0.001) and CSKP infections (CSKP, HR, 3.84; P < 0.001), as well as bile leak (HR, 2.10; P = 0.03) were the strongest predictors of post-LT mortality. In an endemic area, post-LT CRKP infection is common, occurring in 6.6% of recipients, and is strongly associated with post-LT mortality. Improved strategies for screening and prevention of CRKP infection are urgently needed.

Indexed as

CarbapenemsDrug Resistance, BacterialFemaleHumansKlebsiella InfectionsKlebsiella pneumoniaeLiver TransplantationMaleMiddle AgedNew York CityPostoperative ComplicationsRetrospective StudiesRisk FactorsCarbapenems

Identifiers

PMID26136397
PMCPMC4896355
OpenAlexW1831189939

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.